Granite Investment Partners LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, Holdings Channel reports. The firm purchased 53,972 shares of the medical device company’s stock, valued at approximately $3,948,000.

Other large investors have also recently added to or reduced their stakes in the company. Sit Investment Associates Inc. raised its stake in DexCom by 159.8% in the first quarter. Sit Investment Associates Inc. now owns 23,900 shares of the medical device company’s stock worth $2,025,000 after buying an additional 14,700 shares during the last quarter. Morgan Stanley raised its stake in DexCom by 18.0% in the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock worth $177,336,000 after buying an additional 319,631 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp bought a new position in shares of DexCom during the first quarter valued at $270,000. Swiss National Bank raised its position in shares of DexCom by 28.4% in the first quarter. Swiss National Bank now owns 299,500 shares of the medical device company’s stock valued at $25,377,000 after buying an additional 66,200 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in shares of DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock valued at $11,018,000 after buying an additional 7,050 shares in the last quarter.

DexCom, Inc. (NASDAQ DXCM) opened at 69.80 on Friday. The firm’s market capitalization is $6.04 billion. The stock has a 50 day moving average of $71.38 and a 200 day moving average of $75.25. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $96.38.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.24) EPS. Equities research analysts anticipate that DexCom, Inc. will post ($0.77) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Granite Investment Partners LLC Purchases Shares of 53,972 DexCom, Inc. (NASDAQ:DXCM)” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/granite-investment-partners-llc-purchases-shares-of-53972-dexcom-inc-nasdaqdxcm.html.

Several brokerages have weighed in on DXCM. B. Riley reissued a “buy” rating and set a $95.00 price objective on shares of DexCom in a report on Tuesday, May 2nd. William Blair reissued an “outperform” rating on shares of DexCom in a report on Thursday, April 27th. Jefferies Group LLC decreased their price objective on shares of DexCom to $91.00 and set a “buy” rating for the company in a report on Tuesday, May 9th. Piper Jaffray Companies reissued a “buy” rating and set a $78.00 price objective on shares of DexCom in a report on Wednesday, July 12th. Finally, BidaskClub raised shares of DexCom from a “strong sell” rating to a “sell” rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $87.00.

In other DexCom news, CEO Kevin R. Sayer sold 8,649 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total value of $591,505.11. Following the sale, the chief executive officer now owns 347,329 shares of the company’s stock, valued at approximately $23,753,830.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $69.06, for a total transaction of $220,992.00. The disclosure for this sale can be found here. Insiders sold a total of 33,131 shares of company stock worth $2,318,443 in the last three months. Insiders own 1.70% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.